Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) plans to release its third quarter 2022 financial results and corporate highlights on November 3, 2022, after market close. The company specializes in precision medicine, utilizing advanced computational and experimental technologies in drug discovery. Notably, it aims to tackle complex protein targets through its Dynamo™ platform. Notably, no teleconference will follow the financial results release.

Positive

• Innovative Dynamo™ platform enhances drug discovery capabilities.
• Focus on targeted oncology and genetic diseases aligns with market needs.

Negative

• None.

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2022 financial results and corporate highlights after the close of market on Thursday, November 3, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of disparate technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics report its third quarter 2022 financial results?

Relay Therapeutics will report its third quarter 2022 financial results on November 3, 2022, after market close.

What is the focus of Relay Therapeutics in drug discovery?

Relay Therapeutics focuses on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Will there be a teleconference after the financial results release?

No, Relay Therapeutics will not conduct a teleconference following its financial results press release.